Atria Investments Inc Boosts Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Atria Investments Inc raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 135.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,856 shares of the company’s stock after purchasing an additional 17,746 shares during the quarter. Atria Investments Inc’s holdings in Teva Pharmaceutical Industries were worth $556,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. New Covenant Trust Company N.A. bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $28,000. EntryPoint Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $30,000. UMB Bank n.a. lifted its position in shares of Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares during the last quarter. Claro Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $52,000. Finally, Beach Investment Counsel Inc. PA bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $48,000. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TEVA. Barclays lifted their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Finally, UBS Group lifted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $16.80 on Wednesday. The company has a market capitalization of $19.03 billion, a PE ratio of -19.51, a P/E/G ratio of 1.28 and a beta of 0.87. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The company has a 50-day simple moving average of $17.75 and a two-hundred day simple moving average of $17.28. Teva Pharmaceutical Industries Limited has a one year low of $9.04 and a one year high of $19.31.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.